Interestingly, studies by Alam et al. [117] in a lung cancer model and Maitituoheti et al. [129] in a melanoma model showed that KMT2D deficiency led to dysregulation of OXPHOS and glycolytic activity, conferring a vulnerability to perturbation in glycolytic functions. The gene discussed is KMT2D; the disease is melanoma.